0
Abstract: Poster Presentations |

INFLUENCE OF THE ANTIINFLAMMATORY COX-2 INHIBITOR (PARECOXIB) ON EXPERIMENTAL PLEURODESIS INDUCED BY TALC OR SILVER NITRATE FREE TO VIEW

Lisete R. Teixeira, MD, FCCP*; Francisco S. Vargas, MD, FCCP; Milena M. Acencio, BS; Natalia P. Novaes, MD; José Donizeti Costa, Jr, MD; Leila Antonangelo, MD; Evaldo Marchi, MD, FCCP
Author and Funding Information

Pulmonary Division Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil


Chest


Chest. 2007;132(4_MeetingAbstracts):617. doi:10.1378/chest.132.4_MeetingAbstracts.617
Text Size: A A A
Published online

Abstract

PURPOSE: We have previously demonstrated that the anti-inflammatory drugs (corticosteroids or diclofenac) diminish the efficacy of pleurodesis induced by talc (TL) but not by silver nitrate (SN). In clinical practice, anti-inflammatory cyclooxygenase-2 inhibitors (COX-2) are used to control pain and inflammation. The aim of this study was to evaluate the influence of systemic COX2 (Parecoxib) in pleurodesis induced by TL or SN.

METHODS: Forty rabbits received intrapleural injection of 0.5% SN or 400 mg/kg TL. The first group (20 animals) received intramuscular injections of Parecoxib (1mg/Kg/day) during the first seven days, then one injection a week until the end of the study; the second group did not receive COX-2. After 1, 2, 7 or 28 days, five animals in each group were killed and macro and microscopic analyses were performed using scores from 0 to 4. Statistical analysis: t-test.

RESULTS: The systemic injection of COX-2 reduced the gross adhesions at the 2nd and 7th day only in the talc group (*p<0.05); however after 28 days no statistical difference was observed. Microscopic pleural inflammation decreased after 28 days in both groups (*p<0.05). No changes were observed in pleural fibrosis(Figure).

CONCLUSION: The systemic injection of Parecoxib did not interfere in the effectiveness of pleurodesis induced by silver nitrate or talc.

CLINICAL IMPLICATIONS: If these results can be extrapolated to clinical practice, anti-inflammatory cyclooxygenase-2 inhibitors (COX-2) may be used in patients submitted to pleurodesis.

DISCLOSURE: Lisete Teixeira, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543